Literature DB >> 25653853

The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn's disease.

Takayuki Yamamoto1.   

Abstract

Most patients with Crohn's disease (CD) ultimately require one or more operations over their lifetime. Nevertheless, surgery is not a cure and postoperative CD recurrence is common. Ileocolonoscopy has been considered to be the gold standard in the diagnosis and monitoring of postoperative recurrence in patients with CD. However, endoscopy is a time-consuming and invasive procedure. Simple and non-invasive methods for the detection of postoperative recurrence are desirable. Faecal inflammatory biomarkers such as calprotectin and lactoferrin provide an accurate and non-invasive diagnostic and monitoring modality for inflammatory bowel disease. However, there have been limited data on the role of faecal biomarkers in the postoperative setting. Recently, several studies evaluated the value of faecal calprotectin and lactoferrin measurement after surgery for CD. This review was conducted to assess the role of faecal calprotectin and lactoferrin measurements in patients with postoperative CD.

Entities:  

Keywords:  Calprotectin; Crohn’s disease; endoscopic activity; faecal biomarker; lactoferrin; postoperative recurrence; surgery

Year:  2015        PMID: 25653853      PMCID: PMC4315679          DOI: 10.1177/2050640614558106

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  20 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

2.  The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound.

Authors:  A Orlando; I Modesto; F Castiglione; L Scala; D Scimeca; A Rispo; S Teresi; F Mocciaro; V Criscuoli; C Marrone; P Platania; T De Falco; S Maisano; N Nicoli; M Cottone
Journal:  Eur Rev Med Pharmacol Sci       Date:  2006 Jan-Feb       Impact factor: 3.507

3.  Faecal calprotectin but not C-reactive protein (CRP) or Crohn's Disease Activity Index (CDAI) may predict post-operative endoscopic recurrence of Crohn's disease.

Authors:  Konstantinos Papamichael; Pantelis Karatzas; Gerassimos J Mantzaris
Journal:  J Crohns Colitis       Date:  2013-08-13       Impact factor: 9.071

Review 4.  Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.

Authors:  Uri Kopylov; Greg Rosenfeld; Brian Bressler; Ernest Seidman
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

5.  Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease.

Authors:  Delphine Labaere; Annick Smismans; August Van Olmen; Paul Christiaens; Geert D'Haens; Veerle Moons; Pieter-Jan Cuyle; Johan Frans; Peter Bossuyt
Journal:  United European Gastroenterol J       Date:  2014-02       Impact factor: 4.623

6.  Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy.

Authors:  Anders Lasson; Hans Strid; Lena Ohman; Stefan Isaksson; Mikael Olsson; Britt Rydström; Kjell-Arne Ung; Per-Ove Stotzer
Journal:  J Crohns Colitis       Date:  2014-01-11       Impact factor: 9.071

7.  Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study.

Authors:  Dario Sorrentino; Giovanni Terrosu; Alberto Paviotti; Marco Geraci; Claudio Avellini; Giorgio Zoli; Walter Fries; Silvio Danese; Pietro Occhipinti; Tiziano Croatto; Dimitra Zarifi
Journal:  Dig Dis Sci       Date:  2012-01-18       Impact factor: 3.199

8.  A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease.

Authors:  G D Naismith; L A Smith; S J E Barry; J I Munro; S Laird; K Rankin; A J Morris; J W Winter; D R Gaya
Journal:  Aliment Pharmacol Ther       Date:  2013-01-24       Impact factor: 8.171

9.  Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: A prospective pilot study.

Authors:  Takayuki Yamamoto; Manabu Shiraki; Takuya Bamba; Satoru Umegae; Koichi Matsumoto
Journal:  United European Gastroenterol J       Date:  2013-10       Impact factor: 4.623

10.  Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease.

Authors:  C A Lamb; J C Mansfield
Journal:  Frontline Gastroenterol       Date:  2010-11-03
View more
  5 in total

1.  A Role for CXCR3 Ligands as Biomarkers of Post-Operative Crohn's Disease Recurrence.

Authors:  Margaret Walshe; Shadi Nayeri; Jiayi Ji; Cristian Hernandez-Rocha; Ksenija Sabic; Liangyuan Hu; Mamta Giri; Shikha Nayar; Steven Brant; Dermot P B McGovern; John D Rioux; Richard H Duerr; Judy H Cho; Phil L Schumm; Mark Lazarev; Mark S Silverberg
Journal:  J Crohns Colitis       Date:  2022-07-14       Impact factor: 10.020

Review 2.  Disease monitoring in inflammatory bowel disease.

Authors:  Shannon Chang; Lisa Malter; David Hudesman
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 3.  Fecal calprotectin in inflammatory bowel disease.

Authors:  Natalie E Walsham; Roy A Sherwood
Journal:  Clin Exp Gastroenterol       Date:  2016-01-28

4.  Fecal marker levels as predictors of need for endoscopic balloon dilation in Crohn's disease patients with anastomotic strictures.

Authors:  Susana Lopes; Patrícia Andrade; Eduardo Rodrigues-Pinto; Joana Afonso; Guilherme Macedo; Fernando Magro
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

Review 5.  From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.

Authors:  Maria Gloria Mumolo; Lorenzo Bertani; Linda Ceccarelli; Gabriella Laino; Giorgia Di Fluri; Eleonora Albano; Gherardo Tapete; Francesco Costa
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.